$504 Billion is the total value of SENZAR ASSET MANAGEMENT, LLC's 74 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 43.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVRO | Sell | NEVRO CORP | $83,474,650,000 | -26.5% | 1,483,730 | -11.8% | 16.57% | +31.2% |
| AMGN | New | AMGEN INC | $40,376,149,000 | – | 269,300 | +100.0% | 8.02% | – |
| AGN | Buy | ALLERGAN PLC | $38,528,776,000 | -1.0% | 143,748 | +15.5% | 7.65% | +76.8% |
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDadr | $29,906,150,000 | -64.4% | 558,889 | -56.4% | 5.94% | -36.5% |
| ANTM | New | ANTHEM INC | $28,451,253,000 | – | 204,700 | +100.0% | 5.65% | – |
| AET | Sell | AETNA INC NEW | $22,470,000,000 | -61.2% | 200,000 | -62.7% | 4.46% | -30.7% |
| HWAY | Sell | HEALTHWAYS INC | $22,414,743,000 | -31.0% | 2,221,481 | -12.0% | 4.45% | +23.2% |
| SHPG | New | SHIRE PLCsponsored adr | $20,748,330,000 | – | 120,700 | +100.0% | 4.12% | – |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $20,103,326,000 | -26.0% | 1,471,693 | +2.7% | 3.99% | +32.1% |
| RTRX | Buy | RETROPHIN INC | $15,225,327,000 | -25.5% | 1,114,592 | +5.3% | 3.02% | +33.1% |
| LH | New | LABORATORY CORP AMER HLDGS | $14,852,084,000 | – | 126,800 | +100.0% | 2.95% | – |
| INSM | Buy | INSMED INC | $14,000,325,000 | +11.9% | 1,104,998 | +60.4% | 2.78% | +99.9% |
| ALDR | Sell | ALDER BIOPHARMACEUTICALS INC | $12,577,329,000 | -31.7% | 513,570 | -7.8% | 2.50% | +22.0% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $11,162,440,000 | -30.9% | 89,500 | -33.8% | 2.22% | +23.4% |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $11,086,993,000 | +37.8% | 1,199,891 | +121.3% | 2.20% | +146.2% |
| ITCI | Buy | INTRA CELLULAR THERAPIES INC | $10,645,287,000 | -43.9% | 382,924 | +8.5% | 2.11% | +0.1% |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $10,425,682,000 | -14.2% | 1,599,031 | +6.8% | 2.07% | +53.3% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $9,952,054,000 | +83.8% | 338,851 | +106.6% | 1.98% | +228.2% |
| ELOS | Sell | SYNERON MEDICAL LTD | $9,268,948,000 | -14.5% | 1,267,982 | -9.8% | 1.84% | +52.6% |
| TNDM | Sell | TANDEM DIABETES CARE INC | $7,747,101,000 | -29.5% | 889,449 | -4.4% | 1.54% | +26.0% |
| SEM | Buy | SELECT MED HLDGS CORP | $7,636,629,000 | +30.3% | 646,624 | +31.4% | 1.52% | +132.5% |
| ANIP | Sell | ANI PHARMACEUTICALS INC | $7,535,498,000 | -63.2% | 223,871 | -50.7% | 1.50% | -34.3% |
| CORI | Buy | CORIUM INTL INC | $6,700,829,000 | -37.6% | 1,735,966 | +31.4% | 1.33% | +11.5% |
| ITEK | Buy | INOTEK PHARMACEUTICALS CORP | $5,534,460,000 | +57.8% | 747,900 | +141.6% | 1.10% | +181.8% |
| DERM | Buy | DERMIRA INC | $5,445,044,000 | -36.4% | 263,300 | +6.4% | 1.08% | +13.6% |
| ACOR | Sell | ACORDA THERAPEUTICS INC | $4,890,658,000 | -77.3% | 184,902 | -63.3% | 0.97% | -59.5% |
| LCI | New | LANNET INC | $4,869,788,000 | – | 271,600 | +100.0% | 0.97% | – |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $4,089,899,000 | +10.7% | 2,076,091 | +6.8% | 0.81% | +97.6% |
| TKAI | New | TOKAI PHARMACEUTICALS INC | $3,574,187,000 | – | 637,110 | +100.0% | 0.71% | – |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $3,361,696,000 | -26.7% | 1,616,200 | +6.8% | 0.67% | +30.8% |
| BOTA | Buy | BIOTA PHARMACEUTIALS INC | $3,060,264,000 | -17.4% | 2,040,176 | +6.8% | 0.61% | +47.6% |
| Buy | NEURODERM LTD | $3,041,448,000 | -11.6% | 215,400 | +6.8% | 0.60% | +58.1% | |
| ADRO | New | ADURO BIOTECH INC | $2,737,241,000 | – | 213,680 | +100.0% | 0.54% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $2,563,916,000 | -32.0% | 412,869 | +6.8% | 0.51% | +21.5% |
| ZGNX | Sell | ZOGENIX INC | $2,481,864,000 | -55.4% | 268,600 | -28.9% | 0.49% | -20.4% |
| SIEN | Sell | SIENTRA INC | $2,148,211,000 | -37.5% | 314,066 | -45.9% | 0.43% | +11.8% |
| ALQA | Sell | ALLIQUA BIOMEDICAL INC | $578,995,000 | -73.3% | 706,091 | -30.4% | 0.12% | -52.3% |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -223,700 | -100.0% | -0.55% | – |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -441,500 | -100.0% | -0.60% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -135,535 | -100.0% | -0.62% | – |
| DVA | Exit | DAVITA HEALTHCARE PARTNERS I | $0 | – | -94,800 | -100.0% | -0.74% | – |
| SPNC | Exit | SPECTRANETICS CORP | $0 | – | -1,092,512 | -100.0% | -1.83% | – |
| CNC | Exit | CENTENE CORP DEL | $0 | – | -260,000 | -100.0% | -1.90% | – |
| MNKKQ | Exit | MALLINCKRODT PUB LTD CO | $0 | – | -291,940 | -100.0% | -2.42% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -86,300 | -100.0% | -2.94% | – |
| STJ | Exit | ST JUDE MED INC | $0 | – | -506,900 | -100.0% | -3.48% | – |
| MYL | Exit | MYLAN N V | $0 | – | -785,284 | -100.0% | -4.72% | – |
| VRX | Exit | VALEANT PHARMACEUTICALS INTL | $0 | – | -1,299,056 | -100.0% | -14.68% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CONCERT PHARMACEUTICALS INC | 16 | Q2 2018 | 4.5% |
| SANOFI | 14 | Q2 2018 | 17.6% |
| CORIUM INTL INC | 14 | Q3 2017 | 2.3% |
| FOAMIX PHARMACEUTICALS LTD | 14 | Q2 2018 | 2.1% |
| RETROPHIN INC | 13 | Q2 2017 | 3.0% |
| ALDER BIOPHARMACEUTICALS INC | 12 | Q2 2018 | 3.9% |
| RIGEL PHARMACEUTICALS INC | 12 | Q3 2016 | 1.8% |
| INSMED INC | 11 | Q3 2017 | 6.2% |
| TEVA PHARMACEUTICAL INDS LTD | 10 | Q1 2016 | 12.3% |
| ORTHOFIX INTL N V | 10 | Q1 2017 | 9.0% |
View SENZAR ASSET MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corium International, Inc.Sold out | February 14, 2018 | 0 | 0.0% |
| Aviragen Therapeutics, Inc. | February 13, 2017 | 1,774,876 | 4.6% |
| CONCERT PHARMACEUTICALS, INC. | February 13, 2017 | 400,588 | 1.8% |
| Foamix Pharmaceuticals Ltd. | February 13, 2017 | 550,997 | 1.5% |
| NEVRO CORPSold out | February 13, 2017 | 0 | 0.0% |
| TIVITY HEALTH, INC. | February 13, 2017 | 383,200 | 1.0% |
| HEALTHWAYS, INC | February 12, 2016 | 2,525,044 | 7.0% |
| Sientra, Inc. | February 12, 2016 | 580,851 | 3.2% |
| Biota Pharmaceuticals, Inc. | January 15, 2016 | 2,025,976 | 5.2% |
View SENZAR ASSET MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-10-31 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| SC 13G/A | 2018-02-14 |
| 13F-HR | 2018-02-13 |
| 13F-HR | 2017-11-13 |
| 13F-HR | 2017-08-11 |
| 13F-HR | 2017-05-12 |
| 13F-HR | 2017-02-14 |
| SC 13G/A | 2017-02-13 |
View SENZAR ASSET MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.